Terry Rosen recounts how his high school mentor taught critical thinking by asking the class to heat water to 115°C. This impossible task forced students to rely on observation and scientific principles over blindly following instructions, instilling a foundational mindset for a career in science.
Terry Rosen saw an opportunity as big pharma culturally shifted from deep R&D towards an asset-management model. He founded Arcus to fill this gap, building a company focused on the small molecule drug discovery expertise that the industry was starting to abandon, creating a counter-cyclical advantage.
Arcus navigated its capital-intensive early years by using strategic collaborations to bring in over $1 billion in largely non-dilutive funding. This approach allowed the company to reach late-stage clinical milestones and generate valuable data, bridging the gap to a point where public market investors could see tangible value.
Reflecting on his PhD, Terry Rosen emphasizes that experiments that fail are often the most telling. Instead of discarding negative results, scientists should analyze them deeply. Understanding *why* something didn't work provides critical insights that are essential for iteration and eventual success.
Arcus's strategy isn't to find novel targets, but to leverage its small-molecule expertise on validated targets that are difficult to drug. This de-risks the biology and creates a competitive moat based on technical execution, allowing them to develop a clearly better molecule against incumbents like Merck.
Terry Rosen advises against the 'single asset' biotech model, advocating for building a sustainable discovery engine. To fund this, founders must embrace strategic collaborations, even if it means giving up some ownership. This mindset of sharing in a larger, de-risked success is more viable than betting everything on one program.
Arcus's HIF2 inhibitor strategy focuses on a 'TKI-sparing' regimen, which delays the need for more toxic therapies. This offers patients a significantly better quality of life for several years. This value proposition creates a distinct therapeutic category, not just an incremental improvement over competitors.